Teva inks deal with Royalty Pharma on potential vitiligo drug

Royalty Pharma (Nasdaq: RPRX) and the US affiliate of Israel’s Teva Pharmaceutical Industries (NYSE and TASE: TEVA) have announced a funding agreement of up to $500 million to accelerate the clinical development of Teva’s anti-interleukin (IL)-15 antibody, TEV-'408.

IL-15 is a key cytokine involved in multiple immune-mediated disease pathways. Emerging Phase Ib data from the ongoing TEV-‘408 vitiligo study provides preliminary support for IL-15 as a potential therapeutic target to treat a broad variety of autoimmune conditions. Teva anticipates sharing results from TEV-‘408 trials during 2026.

"We are delighted to enter into this second collaboration with Teva as they advance the development of TEV-‘408,” said Pablo Legorreta, chief executive and chairman of Royalty Pharma, adding: “Vitiligo is a chronic autoimmune skin disease that can have a profound emotional and psychosocial burden, yet current treatment options are insufficient. Our continued collaboration underscores Royalty Pharma’s role as a long-term, trusted partner with a focus on funding innovation in potentially transformative and practice changing therapies.”